Capricor surges on amended plans for lead drug (CAPR:NASDAQ)
· seekingalpha.com
Capricor Therapeutics (CAPR) stock surges as the company plans a revised marketing application for lead drug Deramiocel in Duchenne muscular dystrophy. Read more here.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...